Achillion Pharmaceuticals (ACHN) Stock Rating Upgraded by Barclays

Achillion Pharmaceuticals (NASDAQ:ACHN) was upgraded by Barclays from an “underweight” rating to an “equal weight” rating in a research report issued to clients and investors on Monday, May 21st, Marketbeat Ratings reports. The brokerage currently has a $5.00 target price on the biopharmaceutical company’s stock. Barclays’ target price suggests a potential upside of 67.22% from the stock’s current price.

Other equities research analysts also recently issued research reports about the stock. BidaskClub raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, March 6th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Tuesday, April 24th. B. Riley began coverage on shares of Achillion Pharmaceuticals in a research note on Thursday, February 8th. They set a “neutral” rating and a $3.50 price target on the stock. Finally, ValuEngine raised shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. Achillion Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $4.88.

Shares of Achillion Pharmaceuticals traded up $0.01, reaching $2.99, during midday trading on Monday, Marketbeat Ratings reports. 1,002,651 shares of the company were exchanged, compared to its average volume of 1,659,160. Achillion Pharmaceuticals has a one year low of $2.58 and a one year high of $5.66. The firm has a market cap of $428.85 million, a price-to-earnings ratio of -4.82 and a beta of 0.86.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.01). equities research analysts anticipate that Achillion Pharmaceuticals will post -0.56 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System raised its stake in shares of Achillion Pharmaceuticals by 11.9% in the first quarter. California State Teachers Retirement System now owns 206,482 shares of the biopharmaceutical company’s stock valued at $766,000 after acquiring an additional 22,017 shares during the period. Element Capital Management LLC purchased a new position in Achillion Pharmaceuticals in the 1st quarter worth about $163,000. A.R.T. Advisors LLC increased its stake in Achillion Pharmaceuticals by 39.7% in the 1st quarter. A.R.T. Advisors LLC now owns 185,913 shares of the biopharmaceutical company’s stock worth $689,000 after buying an additional 52,800 shares during the period. UBS Group AG increased its stake in Achillion Pharmaceuticals by 213.6% in the 1st quarter. UBS Group AG now owns 305,137 shares of the biopharmaceutical company’s stock worth $1,132,000 after buying an additional 207,824 shares during the period. Finally, Opaleye Management Inc. increased its stake in Achillion Pharmaceuticals by 148.9% in the 1st quarter. Opaleye Management Inc. now owns 1,095,100 shares of the biopharmaceutical company’s stock worth $4,063,000 after buying an additional 655,100 shares during the period. 80.78% of the stock is currently owned by institutional investors and hedge funds.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply